biostar-8k110909.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 4, 2009
BIOSTAR
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Maryland
(State
or other jurisdiction of incorporation)
|
333-147363
(Commission File
Number)
|
20-5101287
(IRS
Employer Identification
No.)
|
|
No.
588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People’s Republic of
China
(Address
of principal executive offices)
|
712046
(Zip
Code)
|
Registrant’s
telephone number, including area code: 86-029-33686638
Copies
to:
Benjamin
Tan, Esq.
Sichenzia
Ross Friedman Ference LLP
61
Broadway, 32 Floor
New York,
New York 10006
Phone:
(212) 930-9700
Fax:
(212) 930-9725
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
r Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
r Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
r Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
r Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
On
November 4 and November 6, 2009, Biostar Pharmaceuticals, Inc. (the “Company”)
issued press releases annexed as Exhibit 99.1 and 99.2 hereto.
On
November 9, 2009, the Company issued a press release announcing a conference
call to discuss its 2009 third quarter performance at 9:30 a.m. ET on Thursday,
November 12, 2009. A copy of the press release is annexed as Exhibit
99.3 hereto.
The
information in this report, including Exhibit 99.1, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or
incorporated subject to the liabilities of that section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and
shall not be incorporated by reference in any registration statement or other
document filed under the Securities Act or the Exchange Act, whether made before
or after the date hereof, regardless of any general incorporation language in
such filings, except as shall be expressly set forth by specific reference in
such a filing.
|
Item
9.01.
|
Financial
Statements and Exhibits.
|
| |
|
|
(d)
|
Exhibits
|
|
|
|
|
|
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
BIOSTAR PHARMACEUTICALS, INC.
Dated:
November 9, 2009
By: /s/
Elaine
Zhao
Name:
Elaine Zhao
Title:
Chief Financial Officer